세계의 종양내 암 치료 시장(2023-2030년)

Overview

Intratumoral immunotherapy is a probable therapeutic approach that targets the tumor using it as a vaccine against itself. It is an advantageous method that encloses direct injection into the tumors thereby targeting the regional tumor immunity hindrances directly.

It can even be leveraged to attack any tumor that fibs in proximate anatomical closeness to a tumor with the intent of immediate uptake by tumors. There are distinct types of intratumoral therapies including cytokines, pathogen-associated molecular patterns (PAMPs), oncolytic viruses, cancer gene therapy, monoclonal antibodies, and small molecules.

Market Dynamics: Drivers & Restraints

Increasing Market Developments

The increasing market developments in the global Intratumoral Cancer Therapies market are expected to boost the global market growth during the forecast period. For instance, in January 2023, AstraZeneca, a UK-based, science-driven biopharmaceutical corporation completed the acquisition of Neogene Therapeutics Inc., for $120 million and this acquisition is expected to unlock further routes for AstraZeneca for the treatment of cancer.

Moreover, in 2022, Regeneron completed the acquisition of Checkmate Pharmaceutical, a clinical-stage biopharmaceutical corporation, and its investigational immune activator for probable usage in multiple tumor types. Furthermore, growing awareness, cases and research activites among other factors are also expected to contribute to the global market growth during the forecast period.

Side Effects Associated with these Intratumoral Cancer Therapies

However, the large number of common and uncommon severe side effects cuased by cancer therapy are expected to hamper the global market growth during the forecast period. Furthermore, the lack of approved treatments available, high cost and deficient number of professionals are among the additional factors hampering the global market growth.

Segment Analysis

The global intratumoral cancer therapies market is segmented based on technology, cancer type, end user and region.

Lung Cancer Type is Expected to Dominate Market

Owing to the increase in new product approvals for lung cancer boosting the segment growth, dominating the global market in the forecast period. For instance, in October 2021, the U.S. FDA authorized Tecentriq (atezolizumab) to treat stage II and stage III Non-small cell lung cancer (NSCLC). Moreover, in April 2022, the U.S. FDA authorized Opdivo (nivolumab) for the treatment of NSCLC in adult patients. Furthermore, the growing cases of Lung cancer along with the increasing research activities are also expected to contribute to the dominance of the segment on the global market in the forecast period.

Geographical Analysis

North America is Expected to Dominate the Global Market

North America is expected to dominate the global market during the forecast period due to increasing government investments, growing cancer cases, and increasing product authorizations among others. For instance, in 2023, the US government announced a budget of USD 7.8 billion to the National Cancer Institute (NCI) for cancer research.

The government and private organizations' investment to expand the research and development of cancer therapies in the region is driving the growth of the North America Intratumoral Cancer Therapy Market.

According to the American Cancer Society, around 1.9 million cases of cancer were diagnosed in the US in 2022. Additionally, Gland Pharma has launched the cancer treatment medicine Bortezomib for Injection in the United States in 2022. Furthermore, the presence of various biotechnology and medical device firms in this region is likely to maintain their lead during the forecast period due to increased spending on research and development initiatives and widespread use of technology in the region.

COVID-19 Impact Analysis

Since some individuals with cancer are at raised threat of severe illness if they get COVID-19, owing to their immune systems have been strained by the cancer and/or its therapies. Individuals who were treated for cancer in the history (particularly if it was years ago) are better potential to have normal immune function. Thus, impacting the therapy demand during the forecast period.

Market Segmentation

By Technology

• Monoclonal Antibodies
• Vaccines
• Checkpoint Inhibitors
• Cell Therapies
• Immunes System Modulator
• Adoptive Cell Transfer
• Cytokines

By Cancer Type

• Lung Cancer
• Breast Cancer
• Malenoma
• Prostate Cancer
• Head and Neck Cancer
• Other

By End User

• Hospitals
• Cancer Research Centres
• Clinics

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
• Middle East and Africa

Key Developments

• In July 2022, Merck formed a USD290 million agreement with Orion to design a novel prostate cancer medicine.
• In July 2022, Philogen reported the enrolment of 214 patients for clinical trial 3 of its latest Intratumoral drug Nidlegy for the treatment of locally advanced melanoma cancer.
• In October 2022, Merck collaborated with Moderma to develop and commercialize personalized intratumoral cancer therapy for melanoma cancer.

Competitive Landscape

The major global players in the market include: Hoffmann-La Roche, Pfizer, Bristol-Myers Squibb, Boehringer Ingelheim GmbH, Sanofi, Daiichi Sankyo, AstraZeneca, Immunocore, Ltd, Merck and Co. Inc. and Biogen Inc. among others.

Why Purchase the Report?

• To visualize the global intratumoral cancer therapies market segmentation based on technology, cancer type, end user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of intratumoral cancer therapies market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global intratumoral cancer therapies market report would provide approximately 61 tables, 59 figures and 194 pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Technology
• 3.2. Snippet by Cancer Type
• 3.3. Snippet by End User
• 3.4. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Increasing Market Developments
  • 4.1.2. Restraints
    • 4.1.2.1. Side Effects
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis
• 5.5. Reimbursement Analysis
• 5.6. Patent Analysis
• 5.7. Pipeline Analysis
• 5.8. Epidemiology
• 5.9. SWOT Analysis
• 5.10. DMI Opinion

6. COVID-19 Analysis

• 6.1. Analysis of COVID-19
  • 6.1.1. Scenario Before COVID
  • 6.1.2. Scenario During COVID
  • 6.1.3. Scenario Post COVID
• 6.2. Pricing Dynamics Amid COVID-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During Pandemic
• 6.5. Manufacturers Strategic Initiatives
• 6.6. Conclusion

7. By Technology

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  • 7.1.2. Market Attractiveness Index, By Technology
• 7.2. Monoclonal Antibodies*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Vaccines
• 7.4. Checkpoint Inhibitors
• 7.5. Cell Therapies
• 7.6. Immunes System Modulator
• 7.7. Adoptive Cell Transfer
• 7.8. Cytokines

8. By Cancer Type

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
  • 8.1.2. Market Attractiveness Index, By Cancer Type
• 8.2. Lung Cancer*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Breast Cancer
• 8.4. Malenoma
• 8.5. Prostate Cancer
• 8.6. Head and Neck Cancer
• 8.7. Other Applications

9. By End User

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 9.1.2. Market Attractiveness Index, By End User
• 9.2. Hospital*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Cancer Research Centres
• 9.4. Clinics

10. By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
  • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.2.6.1. U.S.
    • 10.2.6.2. Canada
    • 10.2.6.3. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
  • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.3.6.1. Germany
    • 10.3.6.2. UK
    • 10.3.6.3. France
    • 10.3.6.4. Italy
    • 10.3.6.5. Spain
    • 10.3.6.6. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
  • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.4.6.1. Brazil
    • 10.4.6.2. Argentina
    • 10.4.6.3. Rest of South America
• 10.5. Asia-Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
  • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.5.6.1. China
    • 10.5.6.2. India
    • 10.5.6.3. Japan
    • 10.5.6.4. Australia
    • 10.5.6.5. Rest of Asia-Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
  • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

11. Competitive Landscape

• 11.1. Competitive Scenario
• 11.2. Market Positioning/Share Analysis
• 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

• 12.1. Hoffmann-La Roche*
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio and Description
  • 12.1.3. Financial Overview
  • 12.1.4. Key Developments
• 12.2. Pfizer
• 12.3. Bristol-Myers Squibb, Inc.
• 12.4. Boehringer Ingelheim GmbH
• 12.5. Sanofi
• 12.6. Daiichi Sankyo
• 12.7. AstraZeneca, Inc.
• 12.8. Immunocore, Ltd
• 12.9. Biogen Inc.
• 12.10. Merck and Co. Inc.

LIST NOT EXHAUSTIVE

13. Appendix

• 13.1. About Us and Services
• 13.2. Contact Us